This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future. It is a time of change for this market sector, with OTC product launches, rising skin cancer incidence and acquisitions in the industry, and this report takes those updated details into account in its comprehensive analysis.
The global market for prescription dermatology drugs includes products in the following categories:
- Prescription Acne and Rosacea Drugs (Benzoyl, Retinoids, Antibiotics, Other)
- Prescription Antiaging and Photodamage Drugs (Keratolytics, Moisturizers, Retinoids, Sun-screens, Other Agents)
- Prescription Dermatitis and Seborrhea Drugs (Topical, Systemic, Others)
- Prescription Fungal Infection Drugs (Topical, Systemic)
- Prescription Hair Loss and Hair Removal Drugs (Antiandrogens, Androgen Inhibitors, Others)
- Prescription Hyperpigmentation/Melasma Drugs (Hyperpigmentation/Melasma Agents, Depigmenting Agents)
- Prescription Psoriasis Drugs (Topical, Systemic, Other)
- Prescription Skin Cancer Drugs
- Other Prescription Skin Disorder Drugs (Antiviral Drugs, Antiparasitic Agents)
A poor pipeline of new products has hurt pharmaceutical companies broadly. Reliance on blockbuster drugs is a longshot strategy and major companies are shifting focus to cosmetic medications. By doing this, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology.
This transition will play a role in the future development of the dermatological industry over the forecast period. The global pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come.
It’s a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing. The following are among the trends analyzed in this report:
- Shift in Growth Areas: Since the last edition, some parts of the market experienced growth and others less so. Market watchers will want to stay informed with what innovators are focusing on.
Slow Economic Recovery: The prescription dermatological drug industry was not immune to the recent economic downturn and weak recovery Some product categories fared better than others, and these areas are detailed in the report.
- Medi-Spas: Increasing trend to provide convenience and pampering for customers through the offering of the Medi-Spa. Medi-spas utilize lasers and intense pulsed light technology as well as medical microdermabrasion, photofacials, Botox and Restylane injections, medical peels and other medical beauty procedures.
- Healthcare Reform: In March 2010, the US government enacted the Patient Protection and Affordable Care Act (PPACA). The PPACA includes provisions that have a significant negative impact on sales in many of the dermatology product categories, including an extension of Medicaid and Medicare benefits to new patient populations, an increase in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and a future increase in the initial coverage limit for Medicare patients.
- The “Gray Areas of Medicine”: Treating the whole person is recognized in today’s medicine as an important adjunct of the traditional examination, diagnosis, treatment and recovery, which leads to the role of dermatologists, plastic surgeons and other medical players in this market.
- Cosmetic Dermatologists: The report discusses the debate over a new function for dermatologists in cosmetic procedures.
- Patient Compliance: Drugs are only effective if patients comply with dosage and time of administration. This is an increasing concern for dermatologists and the industry.
- Melanoma Survival Rates Falter: While some other cancers have declined in incidence, melanoma remains a growing problem, and new dermatological aids will be in demand.
- Phosphatidylglycerol and Psoriasis: Researchers now understand more about this lipid and how it may affect psoriasis.
- Aesthetic Medicine: Popularity of aesthetic treatments are driving drug sales.
- New Filler Options: Collagen has been used for twenty years; now two new filler products are being developed and more could be on the way.
- Consumer Confusion: This is a highly competitive market. With information overload on product choices, its up to the industry to educate.
- Genetic Link to Psoriasis: Discovery of a possible block to the pathway that activates T cells could change treatment.
- Rx-to-OTC Switches: Several dermatological products that were prescription are now available OTC.
- Cosmeceuticals: New personal care products, incorporating antioxidants and polypeptides, that go beyond topical moisturizers and anti-wrinkle creams will be a factor in this market.
Teledermatology: The taking of and sending of digital pictures for consultation has changed medical practice in this specialty.
- Reimbursement Issues: The coverage of dermatological drugs can be very limited.
Photodynamic Therapy: A possible replacement for surgical excision of primary skin cancer.
Synthetic Lipids for Skin Healing: Pseudoceramides that are involved in skin cell growth could be used in treating skin diseases in which skin cells grow abnormally.
- Importance of Drug Delivery: Microdermabrasion and novel electrophoretic products are among the delivery systems that could be seen in future products.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
The following companies are profiled in this report:
- Allergan Inc.
- Allergan Inamed Corporation
- Barrier Therapeutics, Inc
- Bayer AG
- PharmaDerm Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Collagenex (now Galderma) Pharmaceuticals
- Galderma S.A.
- Genentech, Inc.
- GlaxoSmithKline Plc
Johnson & Johnson (Janssen Pharmaceutica, Ortho
- Medicis Pharmaceutical Corporation
- Merck & Company, Inc.
- Mylan Pharmaceuticals, Inc,
- Novartis Pharmaceuticals Corporation
- Nycomed Inc.
- Pfizer, Inc.
- Q-Med AB
- Roche Group (F. Hoffmann-La Roche Ltd.)
- Schering (now Merck)-Plough Corporation
- Sinclair Pharma Plc.
- Stiefel Laboratories, Inc.
- Valeant Pharmaceuticals, Inc.
All market data pertains to the global market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2011. Historical data are provided for each of the years 2009 to 2010, and forecast data are provided for each of the years 2011 through 2016. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2011 base year.